Table 2.
Variable
|
Hilar group (n = 83)
|
Lower group (n = 44)
|
P
value
|
Year of procedure | 0.18 | ||
2011-2015 | 48 (57.8) | 31 (70.5) | |
2016-2021 | 35 (42.2) | 13 (29.5) | |
Diameter of SEMS | 1.0 | ||
8 mm | 1 (1.2) | 0 (0) | |
10 mm | 82 (98.8) | 44 (100) | |
USEMS:CSEMS | 35:48 | 20:24 | 0.85 |
USEMS used | |||
BileRush | 2 (2.4) | 1 (2.3) | 1 |
Bonastent | 1 (1.2) | 0 (0) | 1 |
HANARO | 1 (1.2) | 0 (0) | 1 |
Niti-S Large cell | 9 (10.8) | 5 (11.4) | 1 |
WallFlex | 24 (28.9) | 7 (15.9) | 0.13 |
X Suit NIR | 0 (0) | 2 (4.5) | 0.12 |
Zilver | 0 (0) | 1 (2.3) | 0.35 |
Zilver 635 | 4 (4.8) | 6 (13.6) | 0.09 |
CSEMS used | |||
Bonastent | 0 (0) | 1 (2.3) | 0.35 |
HANARO | 3 (3.6) | 1 (2.3) | 1 |
Niti-S Comvi | 11 (13.3) | 7 (15.9) | 0.79 |
WallFlex | 28 (33.7) | 7 (15.9) | 0.038 |
X Suit NIR | 0 (0) | 6 (13.6) | < 0.01 |
Technical success | 83 (100) | 44 (100) | |
Functional success | 81 (97.6) | 41 (93.2) | 0.34 |
Adverse events | 2 (2.4) | 0 (0) | 0.54 |
Pancreatitis | 2 | 0 | |
Mild | 2 | 0 | |
Post-EST bleeding | 1 | 0 | |
Severe | 1 | 0 | |
SEMS shortening 1 | 1 (1.3) | 2 (4.7) | 0.28 |
SEMS dysfunction | 2 (2.4) | 18 (41) | < 0.01 |
Cause of SEMS dysfunction | |||
Ingrowth | 1 | 3 | |
Overgrowth | 1 | 2 | |
Ingrowth and overgrowth | 8 | ||
Top edge closed by CBD wall | 4 | ||
Dislocation | 1 | ||
Observational period, months | 4.16 ± 5.76 | 9.12 ± 12.07 | 0.012 |
Values are presented as n, n (%), or mean ± SD.
The presence or absence of SEMS shortening was confirmed in 79 patients in the Hilar group and 43 patients in the Lower group.
SEMS: Self-expandable metallic stent; USEMS: Uncovered SEMS; CSEMS: Covered SEMS; EST: Endoscopic sphincterotomy; CBD: Common bile duct.